HeiLongJiang ZBD Pharmaceutical Co., Ltd. Class A

HeiLongJiang ZBD Pharmaceutical Co., Ltd. Class A

SSSE:603567
4.50
CNY
-0.16
(-3.43%)
-1.57EPS
4.95BMarket Cap
Apr 26Next Earn
HeiLongJiang ZBD Pharmaceutical Co., Ltd. Class A
SSE:603567
(Shanghai Stock Exchange)

Recent

price

4.50

P/E

ratio

- -

div

yld

2.31%

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.48
1.91
1.96
2.21
5.14
2.82
3.7
3.28
3.88
4.02
4.78
4.48
3.35
2.88
0.85
0.3
Revenue per Share
0.41
0.54
0.61
0.66
1.45
0.6
0.61
0.54
0.48
0.51
0.38
0.2
0.5
0.47
-1.45
-1.57
Basic EPS, GAAP
-0.05
-0.11
0.01
0.43
-0.98
-0.36
0.42
-0.06
0.05
-0.84
-1.02
-0.78
-0.61
-0.03
0.27
- -
Free Cash Flow per Basic Share
0.03
0.03
0.06
0.14
0.62
0.31
0.24
0.27
0.3
0.39
0.17
0.26
0.17
0.34
0.29
0.1
Dividend per Share
1.28
1.82
2.43
2.58
4.71
5.07
5.5
5.86
6.17
6.47
7.48
7.54
8.01
8.29
6.67
6.17
Book Value per Share
1.19
1.57
2.16
2.36
4.49
4.79
5.21
5.56
5.86
6.15
7.09
6.5
6.94
7.01
5.34
4.81
Tangible Book Value per Share
722
722
722
720
403
849
849
849
849
849
865
941
939
940
940
940
Basic Weighted Avg Shares
1,071
1,380
1,415
1,593
2,073
2,392
3,141
2,786
3,297
3,411
4,130
4,219
3,144
2,707
798
286
Sales/Revenue/Turnover
34.29
34.62
40.95
35.36
35.76
21.35
23
26.36
21.69
20.38
11.35
8.5
8.07
31.71
-52.36
-227.39
Operating Margin (%)
57
64
75
96
115
146
118
122
138
156
137
169
190
144
175
- -
Depreciation Expense
296
390
437
477
585
510
521
462
409
436
332
185
473
438
-1,367
-1,476
Net Income, GAAP
14.31
14.84
15.2
15.63
16.43
15.46
19.47
15.82
24.47
18.57
26.83
36.03
2.25
16.63
- -
- -
Effective Tax Rate (%)
27.64
28.24
30.88
29.96
28.23
21.31
16.58
16.6
12.4
12.79
8.04
4.39
15.04
16.19
-171.23
-515.13
Profit Margin (%)
526
371
478
607
2,429
2,437
2,460
2,374
3,363
3,745
3,864
2,515
4,413
4,673
1,063
614
Working Capital
200
150
100
- -
- -
- -
- -
180
1,130
2,140
1,294
470
1,298
1,554
53
5
LT Debt
923
1,319
1,747
2,173
3,982
4,307
4,679
4,983
5,250
5,503
7,051
7,107
8,041
8,291
6,279
5,839
Total Equity
- -
24.06
17.74
14.75
13.67
7.58
8.77
7.29
5.48
4.99
3.59
1.91
4.35
3.85
- -
- -
Return on Invested Capital (%)
- -
26.82
21.03
18.84
15.94
10.55
9.47
7.92
6.6
6.69
4.67
2.68
5.75
4.87
- -
- -
Return on Capital (%)
- -
34.85
28.53
24.24
18.91
12.27
11.61
9.59
8
8.13
5.3
2.62
6.45
5.71
-19.41
-21.83
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
2,636
2,804
3,137
LT Borrowings
506
336
- -
LT Finance Leases
5
4
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
941
941
940
Market Capitalization
6,662
4,121
4,946

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
5,038
4,828
4,569
Cash, Cash Equivalents & STI
55
65
60
Accounts Receivable, Net
2,405
2,317
2,199
Inventories
1,293
1,294
1,220
Total Current Liabilities
3,639
3,671
3,954
Payables & Accruals
- -
- -
- -
ST Debt
2,636
2,804
3,137
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.44%
4.18%
-24.27%
Free Cash Flow
-356.2%
-246.28%
-1,120.68%
Net Income, GAAP
-35.91%
-66.45%
-411.84%
Sales/Revenue/Turnover
-2.95%
-17.33%
-70.51%
Total Cash Common Dividend
10.61%
13.57%
-14.72%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,118
544
367
677
2,707
2025
469
245
- -
-121
798
2026
182
114
112
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.31
0.11
- -
0.04
0.47
2025
0.08
-0.16
- -
-1.06
-1.45
2026
-0.19
-0.1
-0.23
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.19
-0.11
0.24
0.03
0.34
2025
0.04
0.04
- -
0.03
0.29
2026
0.03
0.02
0.01
- -
- -
Business
Heilongjiang ZBD Pharmaceutical Co., Ltd. focuses its efforts on the research, development, manufacturing, and distribution of traditional Chinese medicines across China. The company's diverse portfolio addresses a wide array of health conditions, encompassing cardiovascular, cerebrovascular, respiratory, orthopedic, oncological, digestive, anti-infective, neurological, and genitourinary disorders. Established in 1996, this pharmaceutical enterprise has expanded its reach, incorporating both traditional Chinese medicine preparations and modern biological and chemical agents. Headquartered in Hulin, China, ZBD Pharmaceutical is recognized for its commitment to high-quality development and green manufacturing practices within the industry.